For: | Wang K, Shi M, Yang A, Tomlinson B, Chan JCN, Chow E. Comment on Dawed et al. Genome-Wide Meta-Analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682. Diabetes Care 2022;45:e80-1. [PMID: 35349650 DOI: 10.2337/dc21-2428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Tomlinson B, Li Y, Chan P. Evaluating gliclazide for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2141108] [Reference Citation Analysis] |
2 | Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, 't Hart LM, Giacomini KM, Pearson ER; for MetGen Plus, for the DIRECT Consortium. Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682. Diabetes Care 2022;45:e82-3. [PMID: 35349657 DOI: 10.2337/dci21-0066] [Reference Citation Analysis] |